Why is Pfizer Ltd. falling/rising?

Recent Price Movement and Market Comparison

Pfizer Ltd.'s stock has been on a downward trajectory over the past week, falling by 2.88%, which notably underperforms the Sensex's modest 0.75% decline during the same period. The trend extends over the last month, where the stock has shed 8.16%, significantly more than the Sensex's 1.98% loss. Year-to-date, Pfizer's shares have declined by 6.01%, again underperforming the benchmark index's 2.32% fall. Over the last year, the stock has generated a negative return of 5.64%, contrasting sharply with the Sensex's robust 8.65% gain. Even over a three-year horizon, Pfizer's cumulative return of 12.98% lags behind the Sensex's 36.79%, while over five years, the stock has declined by 5.66% compared to the Sensex's impressive 68.52% rise.

Technical Indicators and Trading Activity

On the technical front, Pfizer is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum. The stock has also experienced a consecutive three-day decline, resulting in a cumulative loss of 3.55% during this period. Despite this, investor participation has shown some resilience, with delivery volume on 16 Jan rising by 4.59% to 7,880 shares compared to the five-day average, indicating that some investors remain engaged. Liquidity remains adequate, supporting trade sizes of approximately ₹0.12 crore based on 2% of the five-day average traded value.

Fundamental Strengths Supporting the Stock

Despite recent price weakness, Pfizer Ltd. exhibits several positive fundamental attributes. The company boasts a high return on equity (ROE) of 18.68%, reflecting efficient management and profitability. Its return on capital employed (ROCE) for the half-year period stands at an impressive 24.41%, underscoring effective utilisation of capital. The firm maintains a conservative capital structure with an average debt-to-equity ratio of zero, indicating minimal leverage risk. Operational cash flow for the year is robust at ₹659.75 crore, while profit after tax (PAT) for the latest six months has grown by 23.20% to ₹380.77 crore. Furthermore, Pfizer has reported positive results for three consecutive quarters, signalling consistent earnings momentum. The majority shareholding by promoters also suggests stable ownership and strategic direction. Additionally, the stock offers a relatively high dividend yield of 3.48%, which may appeal to income-focused investors.

Challenges and Valuation Concerns Weighing on the Stock

However, these positives are tempered by several factors that have contributed to the stock's underperformance. Long-term growth has been modest, with net sales increasing at an annualised rate of just 2.01% and operating profit growing at 7.55% over the past five years. This slow growth trajectory contrasts with the expectations of investors seeking more dynamic expansion. The stock's valuation appears stretched, trading at a price-to-book value of 5.6, which is considered very expensive relative to its historical averages and peers. Although the company’s profits have risen by 15.2% over the past year, the stock has still delivered a negative return of 5.64%, resulting in a price/earnings to growth (PEG) ratio of 2, indicating that the market may be pricing in limited upside. Furthermore, Pfizer has underperformed the BSE500 index over multiple time frames, including the last three years, one year, and three months, highlighting its below-par relative performance in both the short and long term.

Investor Takeaway

In summary, Pfizer Ltd.'s recent share price decline is primarily driven by its underwhelming returns relative to market benchmarks, expensive valuation metrics, and subdued long-term growth prospects. While the company demonstrates strong management efficiency, solid profitability, and a healthy dividend yield, these strengths have not been sufficient to offset concerns about its growth trajectory and relative performance. Investors should weigh these factors carefully, considering both the stock’s fundamental resilience and its challenges before making investment decisions.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →